SCHEMBL5128057

SCHEMBL5128057

CCCC(N)(SC1OC(c2ccccc2)=NN1c1cc(F)cc(F)c1)C(=O)OCNCc1cccc(CC)c1.NC(=O)c1c(NC(=O)CCC(=O)O)sc2c1CCCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.39
CNR2 P34972 1/20 0.37
ALDH1A1 P00352 7/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
GRM1 Q13255 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 4/20 0.36
PDE4D Q08499 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GRIA2 P42262 1/20 0.34
POLB P06746 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5579545 0.84 BACE1 (0.32)
SCHEMBL5128065 0.68 FLT3 (0.40) FLT3CNR2ALDH1A1SMN1; SMN2RXFP1
SCHEMBL5128063 0.66 MAPT (0.42) FLT3CNR2ALDH1A1SMN1; SMN2GRM1
SCHEMBL6698958 0.66 BACE1 (0.51) FLT3ALDH1A1SMN1; SMN2RXFP1MEN1
SCHEMBL5579615 0.66 FLT3 (0.46) FLT3CNR2ALDH1A1SMN1; SMN2RXFP1
SCHEMBL5579626 0.66 FLT3 (0.46) FLT3CNR2ALDH1A1SMN1; SMN2RXFP1
SCHEMBL5579540 0.65 BACE1 (0.33)
SCHEMBL5579788 0.62 HTT (0.34) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL5455950 0.62 HPGD (0.83) FLT3ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5118902 0.62 BACE1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 FLT3 4248/4885CNR2 3869/4885ALDH1A1 2178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.